1985
DOI: 10.1016/0002-9343(85)90259-1
|View full text |Cite
|
Sign up to set email alerts
|

Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

2
19
0
1

Year Published

1986
1986
2014
2014

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 38 publications
(22 citation statements)
references
References 19 publications
2
19
0
1
Order By: Relevance
“…In contrast, ceftazidime monotherapy had no effect on sputum colony counts for any P. cepacia isolate. The absence of an effect on P. cepacia sputum isolates was observed despite the potent activity ceftazidime demonstrated in vitro against this microorganism (Table 2) relative to achievable ceftazidime concentrations in sputum reported previously (2,11). Moreover, a dramatic effect on sputum P. aeruginosa colonization was observed, even though ceftazidime displayed less potency and variable in vitro activity against these isolates.…”
Section: Resultsmentioning
confidence: 73%
See 2 more Smart Citations
“…In contrast, ceftazidime monotherapy had no effect on sputum colony counts for any P. cepacia isolate. The absence of an effect on P. cepacia sputum isolates was observed despite the potent activity ceftazidime demonstrated in vitro against this microorganism (Table 2) relative to achievable ceftazidime concentrations in sputum reported previously (2,11). Moreover, a dramatic effect on sputum P. aeruginosa colonization was observed, even though ceftazidime displayed less potency and variable in vitro activity against these isolates.…”
Section: Resultsmentioning
confidence: 73%
“…Pharmacologic evaluations of ceftazidime in these patients have demonstrated altered biodisposition characteristics (8) similar to those observed for other antimicrobial agents in patients with CF (9,12,16). Our previous experience assessing the sputum penetration characteristics of ceftazidime in patients with CF revealed sputum drug concentrations which equalled or only marginally exceeded the MIC for pseudomonal isolates (2). Despite these potential pharmacologic limitations, numerous studies have documented the clinical efficacy of ceftazidime monotherapy in the treatment of acute pulmonary exacerbations experienced by patients with CF (2,3,6,11).…”
mentioning
confidence: 70%
See 1 more Smart Citation
“…Противосинегнойные пенициллины разных групп примерно одинаковы по эффективности [20]. Из цефало-споринов III поколения высокой эффективностью в отно-шении P. аeruginosa обладает цефтазидим [21].…”
Section: лечение синегнойной инфекцииunclassified
“…The potential for development of broad-spectrum beta-lactam resistance by induction or derepression of chromosomal beta-lactamase has been recognized and has prompted recommendations for careful use of these agents to prevent the spread of multiply resistant bacteria (11). In the treatment of pulmonary P. aeruginosa infections with these agents, the detection of resistant isolates by different groups of researchers has been quite variable (2,(4)(5)(6).…”
mentioning
confidence: 99%